Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 331

1.

The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.

Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K.

J BUON. 2013 Apr-Jun;18(2):335-41.

PMID:
23818343
2.

Association of breast cancer subtypes and body mass index.

Petekkaya I, Sahin U, Gezgen G, Solak M, Yuce D, Dizdar O, Arslan C, Ayyildiz V, Altundag K.

Tumori. 2013 Mar-Apr;99(2):129-33. doi: 10.1700/1283.14180.

PMID:
23748802
3.

Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.

Biglia N, Peano E, Sgandurra P, Moggio G, Pecchio S, Maggiorotto F, Sismondi P.

Gynecol Endocrinol. 2013 Mar;29(3):263-7. doi: 10.3109/09513590.2012.736559. Epub 2012 Nov 23.

PMID:
23174088
4.

Does obesity have an effect on outcomes in triple-negative breast cancer?

Mowad R, Chu QD, Li BD, Burton GV, Ampil FL, Kim RH.

J Surg Res. 2013 Sep;184(1):253-9. doi: 10.1016/j.jss.2013.05.037. Epub 2013 Jun 2.

PMID:
23768767
5.

Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.

Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M.

Eur J Surg Oncol. 2013 Mar;39(3):260-5. doi: 10.1016/j.ejso.2012.12.004. Epub 2013 Jan 10.

PMID:
23313014
6.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

7.

The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.

Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, Abdulkarim B.

Breast Cancer Res Treat. 2010 Nov;124(1):187-94. doi: 10.1007/s10549-010-1135-1. Epub 2010 Sep 3.

PMID:
20814819
8.

The association between body mass index and immunohistochemical subtypes in breast cancer.

Sahin S, Erdem GU, Karatas F, Aytekin A, Sever AR, Ozisik Y, Altundag K.

Breast. 2017 Apr;32:227-236. doi: 10.1016/j.breast.2016.09.019. Epub 2016 Oct 15.

PMID:
27756509
9.

Impact of the obesity on lymph node status in operable breast cancer patients.

Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Solak M, Turkoz FP, Arik Z, Esin E, Petekkaya I, Altundag K.

J BUON. 2013 Oct-Dec;18(4):824-30.

PMID:
24344004
10.

Association between common risk factors and molecular subtypes in breast cancer patients.

Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K.

Breast. 2013 Jun;22(3):344-50. doi: 10.1016/j.breast.2012.08.005. Epub 2012 Sep 14.

PMID:
22981738
11.

Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer.

Zegarac M, Nikolic S, Gavrilovic D, Jevric M, Kolarevic D, Nikolic-Tomasevic Z, Kocic M, Djurisic I, Inic Z, Ilic V, Santrac N.

J BUON. 2013 Oct-Dec;18(4):859-65.

PMID:
24344009
12.

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.

PMID:
23389361
13.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
14.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Oncol Rep. 2010 May;23(5):1213-20.

PMID:
20372832
15.

Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.

Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B.

J BUON. 2015 Jan-Feb;20(1):28-34.

PMID:
25778292
16.

Clinicopathological features of triple-negative breast cancer in Taiwanese women.

Yao-Lung K, Dar-Ren C, Tsai-Wang C.

Int J Clin Oncol. 2011 Oct;16(5):500-5. doi: 10.1007/s10147-011-0211-9. Epub 2011 Apr 1.

PMID:
21455625
17.

Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.

Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, Chirlaque MD, Perucha J, Díaz JM, Mateos A, Machón M, Marcos-Gragera R.

Gynecol Oncol. 2013 Sep;130(3):609-14. doi: 10.1016/j.ygyno.2013.05.039. Epub 2013 Jun 6.

PMID:
23747837
18.

High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital.

Ly M, Antoine M, Dembélé AK, Levy P, Rodenas A, Touré BA, Badiaga Y, Dembélé BK, Bagayogo DC, Diallo YL, Koné AA, Callard P, Bernaudin JF, Diallo DA.

Oncology. 2012;83(5):257-63. doi: 10.1159/000341541. Epub 2012 Sep 4.

PMID:
22964749
19.

Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.

Li J, Liu X, Tong Z.

Jpn J Clin Oncol. 2012 Jun;42(6):471-6. doi: 10.1093/jjco/hys046. Epub 2012 Apr 3.

PMID:
22493058
20.

Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.

Chen X, Yu X, Chen J, Zhang Z, Tuan J, Shao Z, Guo X, Feng Y.

Cancer. 2013 Jul 1;119(13):2366-74. doi: 10.1002/cncr.28085. Epub 2013 Apr 10.

Supplemental Content

Support Center